Previous 10 | Next 10 |
- SENTI-202 on track to submit an Investigational New Drug (IND) application in second half of 2023 for treatment of CD33 and/or FLT3 expressing hematologic malignancies including AML and MDS - - Preclinical data from multiple Gene Circuit enhanced CAR NK programs to be presented at Ameri...
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit technology platform, today announced that Tim Lu, MD, Ph...
– R&D focus is on lead oncology candidate SENTI-202 for the treatment of AML and other CD33 and/or FLT3 expressing hematologic malignancies, and SENTI-401 to target colorectal cancer and other CEA-positive solid tumors – – SENTI-202 on track for IND filing in 2H...
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that Tim Lu, MD, PhD, ...
– ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell therapy candidate engineered with a logic-gated gene circuit and multi-armed with crIL-15, that is advancing toward clinical development for hematologic malignancies – ȁ...
– Review of new preclinical data and clinical development plan for SENTI-202 in hematologic malignancies; also featuring KOL discussion of treatment landscape and unmet need in AML – – Live and webcast event on Sunday, December 11, 11:30 am - 12:30 pm CST ...
Senti Biosciences press release ( NASDAQ: SNTI ): Q3 GAAP EPS of -$0.38 beats by $0.12 . Revenue of $1.77M (+60.9% Y/Y) beats by $0.84M . As of September 30, 2022, Senti Bio held cash and cash equivalents of $114.9 million, which the Company believes is suffici...
- SENTI-202 on track for IND filing in 2023; clinical plans for SENTI-202 expand beyond AML to CD33 and/or FLT3 expressing hematologic malignancies including MDS - - Selected development candidate for program to treat GPC3-expressing solid tumors including HCC, SENTI-301A; e...
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit technology platform, today announced a poster pres...
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that on October 27, 2022...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
0.0%Change Percent:
Senti Biosciences Inc. Company Name:
SNTI Stock Symbol:
NASDAQ Market:
Senti Biosciences Inc. Website:
A look at the top 10 most actives in the United States Zoomcar Holdings Inc. (ZCAR) rose 58.3% to $0.2162 on volume of 130,087,791 shares Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.1863 on volume of 71,767,970 shares SMX (Security Matters) Public Limited Company (SMX) rose 17.1...
A look at the top 10 most actives in the United States Senti Biosciences Inc. (SNTI) rose 51.3% to $0.4175 on volume of 386,768,896 shares NVIDIA Corporation (NVDA) rose 0.6% to $124.3 on volume of 277,459,318 shares PROSHARES TRUST (SQQQ) fell 1.9% to $8.12 on volume of 139,088,335 share...
A look at the top 10 most actives in the United States Complete Solaria Inc Com (CSLR) rose 58.5% to $1.775 on volume of 71,457,263 shares Senti Biosciences Inc. (SNTI) rose 55.1% to $0.428 on volume of 64,207,396 shares Golden Heaven Group Holdings Ltd. (GDHG) rose 13.3% to $0.1711 on vo...